Showing results 1 to 20 of 34
next >
| Preview | Issue Date | Title | Author(s) |
| 2014 | Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from study of coronary atheroma by intravascular ultrasound: effect of rosuvastatin versus atorvastatin | Puri, R.; Nissen, S.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Libby, P.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2015 | Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial | Nicholls, S.; Lincoff, A.; Barter, P.; Brewer, H.; Fox, K.; Gibson, C.; Grainger, C.; Menon, V.; Montalescot, G.; Rader, D.; Tall, A.; McErlean, E.; Riesmeyer, J.; Vangerow, B.; Ruotolo, G.; Weerakkody, G.; Nissen, S. |
| 2015 | Atheroma progression in hyporesponders to statin therapy | Kataoka, Y.; St John, J.; Wolski, K.; Uno, K.; Puri, R.; Tuzcu, E.; Nissen, S.; Nicholls, S. |
| 2017 | Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction | Bayturan, O.; Puri, R.; Tuzcu, E.; Shao, M.; Wolski, K.; Schoenhagen, P.; Kapadia, S.; Nissen, S.; Sanders, P.; Nicholls, S. |
| 2013 | C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy | Puri, R.; Nissen, S.; Libby, P.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2015 | Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib | Nicholls, S.; Ruotolo, G.; Brewer, H.; Kane, J.; Wang, M.; Krueger, K.; Adelman, S.; Nissen, S.; Rader, D. |
| 2017 | Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial | Nicholls, S.; Ray, K.; Ballantyne, C.; Beacham, L.; Miller, D.; Ruotolo, G.; Nissen, S.; Riesmeyer, J. |
| 2016 | Coronary atheroma progression rates in men and women following high-intensity statin therapy: a pooled analysis of REVERSAL, ASTEROID and SATURN | Stegman, B.; Shao, M.; Nicholls, S.; Elshazly, M.; Cho, L.; King, P.; Kapadia, S.; Tuzcu, M.; Nissen, S.; Puri, R. |
| 2013 | Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy | Puri, R.; Nissen, S.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Libby, P.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2013 | Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment- elevation myocardial infarction: an intravascular ultrasound study | Puri, R.; Nicholls, S.; Nissen, S.; Brennan, D.; Andrews, J.; Liew, G.; Nelson, A.; Carbone, A.; Copus, B.; Tuzcu, E.; Beltrame, J.; Worthley, S.; Worthley, M. |
| 2013 | Effect of aliskiren on progression of coronary disease in patients with prehypertension: The AQUARIUS randomized clinical trial | Nicholls, S.; Bakris, G.; Kastelein, J.; Menon, V.; Williams, B.; Armbercht, J.; Brunel, P.; Nicolaides, M.; Hsu, A.; Hu, B.; Fang, H.; Puri, R.; Uno, K.; Kataoka, Y.; Bash, D.; Nissen, S. |
| 2018 | Effect of evolocumab on coronary plaque composition | Nicholls, S.; Puri, R.; Anderson, T.; Ballantyne, C.; Cho, L.; Kastelein, J.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.; Wasserman, S.; Honda, S.; Shishikura, D.; Scherer, D.; Borgman, M.; Brennan, D.; Wolski, K.; Nissen, S. |
| 2016 | Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial | Nicholls, S.; Puri, R.; Anderson, T.; Ballantyne, C.; Cho, L.; Kastelein, J.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.; Wasserman, S.; Scott, R.; Ungi, I.; Podolec, J.; Ophuis, A.; Cornel, J.; Borgman, M.; Brennan, D.; Nissen, S. |
| 2015 | Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: insights from AQUARIUS | Puri, R.; Nissen, S.; Menon, V.; Shao, M.; Hsu, A.; Bakris, G.; Kastelein, J.; Williams, B.; Armbrecht, J.; Brunel, P.; Kataoka, Y.; Nicholls, S. |
| 2014 | Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study | Sjouke, B.; Langslet, G.; Ceska, R.; Nicholls, S.; Nissen, S.; Öhlander, M.; Ladenson, P.; Olsson, A.; Hovingh, G.; Kastelein, J. |
| 2016 | Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients | Nicholls, S.; Ruotolo, G.; Brewer, H.; Wang, M.; Liu, L.; Willey, M.; Deeg, M.; Krueger, K.; Nissen, S. |
| 2013 | Exploring coronary atherosclerosis with intravascular imaging | Puri, R.; Tuzcu, E.; Nissen, S.; Nicholls, S. |
| 2018 | Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation | Nicholls, S.; Tuzcu, E.; Wolski, K.; Johnson, B.; Sopko, G.; Sharaf, B.; Pepine, C.; Nissen, S.; Merz, C. |
| 2013 | Factors underlying regression of coronary atheroma with potent statin therapy | Puri, R.; Nissen, S.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Libby, P.; Raichlen, J.; St. John, J.; Wolski, K.; Uno, K.; Kataoka, Y.; Nicholls, S. |
| 2014 | Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy | Kataoka, Y.; Puri, R.; Hammadah, M.; Duggal, B.; Uno, K.; Kapadia, S.; Tuzcu, E.; Nissen, S.; Nicholls, S. |
